Raclopride

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Raclopride
DrugBank Accession Number
DB12518
Background

Raclopride has been used in trials studying Parkinson Disease.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 347.24
Monoisotopic: 346.0850979
Chemical Formula
C15H20Cl2N2O3
Synonyms
  • Racloprida
  • Raclopride
  • Raclopridum
External IDs
  • FLA 870

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UDopamine D2 receptor
antagonist
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Raclopride is combined with 1,2-Benzodiazepine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Raclopride.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Raclopride.
AclidiniumRaclopride may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Raclopride.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Raclopride.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Raclopride.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Raclopride.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Raclopride.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Raclopride.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylamides
Alternative Parents
Methoxyphenols / 3-halobenzoic acids and derivatives / Benzamides / Benzoyl derivatives / Dichlorobenzenes / Anisoles / Methoxybenzenes / O-chlorophenols / P-chlorophenols / Phenoxy compounds
show 12 more
Substituents
1,3-dichlorobenzene / 2-chlorophenol / 2-halophenol / 3-halobenzoic acid or derivatives / 4-chlorophenol / 4-halophenol / Alkyl aryl ether / Amine / Amino acid or derivatives / Anisole
show 34 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
430K3SOZ7G
CAS number
84225-95-6
InChI Key
WAOQONBSWFLFPE-VIFPVBQESA-N
InChI
InChI=1S/C15H20Cl2N2O3/c1-3-19-6-4-5-9(19)8-18-15(21)12-13(20)10(16)7-11(17)14(12)22-2/h7,9,20H,3-6,8H2,1-2H3,(H,18,21)/t9-/m0/s1
IUPAC Name
3,5-dichloro-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-hydroxy-6-methoxybenzamide
SMILES
CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC

References

General References
Not Available
PubChem Compound
3033769
PubChem Substance
347828748
ChemSpider
2298373
BindingDB
50005118
ChEBI
92070
ChEMBL
CHEMBL8809
ZINC
ZINC000025757754
Wikipedia
Raclopride

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceEating Disorder1
1CompletedBasic ScienceDepression1
0RecruitingBasic ScienceNormal Physiology / Opioid Related Disorders1
0SuspendedBasic ScienceCocaine Abuse1
Not AvailableCompletedNot AvailableHealthy Volunteers / Parkinson's Disease (PD)1
Not AvailableRecruitingBasic ScienceBMI >27 kg/m2 / BMI >30 kg/m2 / Healthy Volunteers1
Not AvailableWithdrawnNot AvailableSchizophrenia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.126 mg/mLALOGPS
logP3.19ALOGPS
logP2ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)6.26ChemAxon
pKa (Strongest Basic)8.47ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.8 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity88.07 m3·mol-1ChemAxon
Polarizability35.02 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0119000000-60d7b9266bbc9f46e57c

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y, Perez A, Frankle WG, Cooper T, Kleber HD, Fischman MW, Laruelle M: Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology. 2004 Jun;29(6):1190-202. [Article]

Drug created on October 20, 2016 22:41 / Updated on February 21, 2021 18:53